Screening ERG-BAF Protein Interactions Using SILAC Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to identify compounds that interfere with the interaction between ERG or ETV proteins and the mSWI/SNF (BAF) chromatin remodeling complex, which is crucial for understanding the mechanism of action in prostate cancer and developing therapeutic approaches.
Innovation Solution
A method is described for screening compounds that interfere with the interaction between ERG or ETV proteins and the mSWI/SNF (BAF) chromatin remodeling complex by administering candidate compounds at varying concentrations and assessing the strength of protein interactions using techniques such as SILAC mass spectrometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional screening methods are used to identify compounds interfering with ERG-BAF interaction, then the screening process can be performed with standard techniques, but the ability to detect and measure the interaction strength is insufficient
Solution Approach 1:
The patent introduces an intermediary assay system that mediates the detection of ERG-BAF protein interactions. The screening method uses a cellular assay where ERG protein expression levels serve as the intermediary indicator of BAF complex interaction strength. By measuring ERG protein levels as a proxy for interaction strength, the patent achieves precise measurement without directly complicating the screening apparatus.
Solution Approach 2:
The patent replaces direct mechanical or biochemical measurement of protein-protein interaction with a biological readout system. Instead of using complex biophysical methods to measure ERG-BAF binding, the invention substitutes this with a cellular-based assay that measures ERG protein expression levels, which reflect the functional outcome of the interaction. This substitution simplifies the measurement approach while maintaining precision.
2Measurement precision
If the screening method uses multiple concentration points to assess interaction strength, then the measurement accuracy improves, but the time required for screening increases
Solution Approach 1:
The patent applies partial action by using a limited number of concentration points (at least two different concentrations) rather than exhaustive testing. This approach provides sufficient precision to assess interaction strength while avoiding the time cost of testing every possible concentration. The method identifies active compounds efficiently by comparing results across a minimal necessary set of concentration conditions.
3Reliability
If the patent focuses on identifying compounds that interfere with ERG-BAF interaction specifically, then the therapeutic relevance to prostate cancer is improved, but the scope of applicable compounds is reduced
Solution Approach 1:
The patent creates a universal screening platform that, while specifically designed to identify ERG-BAF interaction inhibitors, can accommodate various compound types and delivery methods. The assay system is adaptable to different chemical structures, natural products, and molecular entities. The core methodology remains applicable across diverse compound classes, allowing the same platform to screen for therapeutics relevant to multiple prostate cancer mechanisms involving ERG dysregulation.
Data Source
AI summary
The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.